Sp296effect of Febuxostat Versus Allopurinol on Hyperuricemia and Progression of Chronic Kidney Disease

Nagaraju, Shankar Prasad; Attur, Ravindra Prabhu; Rangaswamy, Dharshan; Rao, Indu Ramachandra; Rao, Satish; Kaza, Sindhu; Shenoy, Srinivas Vinayak; Saraf, Karan; Bhojaraja, Mohan V; Ramaswamy, Ashok; Laxminarayana, Sindhura Lakshmi Koulmane; Kosuru, Srinivas; Parthasarathy, R.

doi:10.1093/ndt/gfx145.sp296

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of CrGN varies with geographic location and policies of kidney biopsies from 2-10% in different studies [6]. In our study we got 3.5% diffuse CrGN which is closer to study of Nagaraju SP, et al in Southern India population [7].…”

Section: Discussionsupporting

confidence: 85%

“…[13]. Male: female ration (0.72) of our study population was discordant with some studies, who got mostly male affected by CrGN [7,16]. In our study female predominance is probably due the large number of IC-CrGN cases.…”

Section: Discussionsupporting

confidence: 76%

“…Anti GBM diseases accounts for 6.97% of CrGN cases in our study, which is quite closer to study by McAdoo SP, et al in London (5%) [12], Rampelli SK, et al (2.5%) [8] and Kumar R,et al (3%) [11] in India. While anti GBM diseases were found in higher number in study carried out by Nagaraju SP,et al (24%) in India [7] and Jennette JC (15%) in USA [1]. It is possibly due to geographical, racial variation of study population and some of the studies were of small cohort.…”

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Immunohistological Spectrum of Diffuse Crescentic Glomerlonephritis, a Single Center Study in Bangladesh

Islam¹

2019

CPRJ

View full text Add to dashboard Cite

Background: Diffuse Crescentic glomerulonephritis (CrGN) is defined as presence of crescents in >50% of glomeruli sampled for renal biopsy. This is a critical diagnosis with clinical implications that ideally is communicated to the referring physician immediately. There is limited data on the etiology, clinical and histopathological spectrum of CrGN in Bangladeshi population. Aim: This study aims to identify the aetiology, clinico-pathological features and immunohistological patterns of crescentic glomerulonephritis in Bangladeshi population. Materials and Methods: All the crescentic glomerulonephritis diagnosed histologically at Armed Forces Institute of Pathology, Dhaka irrespective of age and sex are included in the study. The study duration was from January 2017 to December 2018. The renal biopsy samples were undergone H&E, PAS, Masson trichrome and Methanamine silver staining. For each case direct immunofluoresnece study was carried out for IgG, IgM, IgA, C3, C1q, Kappa and Lambda. Depending on clinical, biochemical, serological, histological and immunofluorescence evaluation crescentic glomerulonephritis was classified. Results: During stipulated period 43 crescentic glomerulonephritis were diagnosed which comprises 3.5% out of total 1229 non transplant renal core biopsy patients. Mean age was 30.32+ 17.41 the largest age group (15/43) being paediatric age group (<16 yrs). The male female ratio was 0.72. The most common presentation was generalized body swelling (46.51%) followed by gross haematuria (27.9%). On urine examination 38 (88.37%) patients had haematuria

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Immunohistological Spectrum of Diffuse Crescentic Glomerlonephritis, a Single Center Study in Bangladesh

Islam¹

2019

CPRJ

View full text Add to dashboard Cite

show abstract

“…As part of the initial screening of titles and abstracts, we excluded 171 citations, and the 33 articles were to be retrieved for full text review, 28 were excluded: 18 did not report baseline eGFR and/or outcomes related to renal function, 8 did not meet the inclusion criteria, and 2 measured serum creatinine in hyperuricemic patients with CKD undergoing febuxostat therapy. Therefore, 5 randomized, double-blind, controlled trials [ 22 – 26 ] were included in the meta-analysis: 3 RCT studies comparing febuxostat with allopurinol in hyperuricemic patients with CKD [ 23 , 25 , 26 ] and 2 comparing febuxostat with placebo in hyperuricemic patients with CKD. [ 22 , 24 ]…”

Section: Resultsmentioning

confidence: 99%

“…Among them, 437 subjects were randomized to receive febuxostat. Three studies were conducted in Eastern countries [ 22 , 23 , 26 ] and 2 were conducted in Western countries. [ 24 , 25 ] One of the studies (comparing febuxostat vs placebo) did not provide the mean age and SD for each group of patients, [ 24 ] whereas the others included CKD patients >18 years old.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease

Zeng

Tang

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:To investigate the efficacy of febuxostat in hyperuricemic patients with chronic kidney disease (CKD), relevant randomized clinical trials (RCTs) were analyzed.Methods:We used PubMed, Medline, ISI Web of Science, CBMdisc, and Cochrane Library databases to conduct a systematic literature research. A fixed-effects model was used to evaluate the standardized mean differences (SMDs) with 95% confidence intervals (CIs). We conducted subgroup analysis, sensitivity analysis, and analyzed publication bias, to comprehensively estimate the renoprotective effects of febuxostat in hyperuricemic patients with CKD.Results:Among 296 retrieved studies, 5 relevant RCTs were included in the meta-analysis. The result showed that serum estimated glomerular filtration rate (eGFR) was improved after febuxostat treatment in hyperuricemic patients with CKD, with an SMD (95% CI) of 0.24 [−0.17 to 0.43] and P = .67 (fixed-effects model). No heterogeneity was observed across studies (I2 = 0% and P = .67). Subgroup analysis suggested that treatment-related reductions in serum eGFR levels were not related to drug doses, intervention times, or region.Conclusions:The present meta-analysis suggests that febuxostat may slow the progression of mild-to-moderate CKD. Given the limited number of included studies, additional large sample-size RCTs are required to determine the long-term renoprotective effects of febuxostat in hyperuricemic patients with CKD.

show abstract

Sp296effect of Febuxostat Versus Allopurinol on Hyperuricemia and Progression of Chronic Kidney Disease

Cited by 2 publications

References 0 publications

Immunohistological Spectrum of Diffuse Crescentic Glomerlonephritis, a Single Center Study in Bangladesh

Immunohistological Spectrum of Diffuse Crescentic Glomerlonephritis, a Single Center Study in Bangladesh

Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease

Contact Info

Product

Resources

About